/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Brokers Promotions
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
+0.15%
Natural Gas
+0.74%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+0.80%
VIX
N/A
Economic Calendar
EUR/USD
+0.15%
Natural Gas
+0.74%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+0.80%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
Five Things to Know in Crypto This Week: BTC-Spot ETFs Enjoy 4 Week Inflow Streak
about 2 hours ago
Can Silver Reach $35 In 2024?
about 14 hours ago
Core PCE Inflation Matches Estimates for April
about 19 hours ago
Euro Area Inflation Rises to 2.6%, Core CPI Jumps to 2.9%
about 20 hours ago
German Retail Sales Slide by 1.2% in April as Food Sales Slump
1 day ago
China NBS Manufacturing PMI Falls to 49.5 While the Hang Seng Jumps 1.43%
1 day ago
Crude Oil News Today: Will OPEC+ Extend Production Cuts into 2025?
about 1 hour ago
XRP News Today: Ripple CEO Calls for SEC Chair’s Resignation Amid ETF Speculations
about 5 hours ago
Bitcoin (BTC) News Today: BTC-Spot ETF Outflows and the SAB 121 Veto
about 6 hours ago
Gold Price Forecast: Drops Below Key Levels, Signals Further Weakness
about 11 hours ago
Natural Gas Price Forecast: Intraday Bounce in Natural Gas Sparks Short-Term Optimism
about 11 hours ago
NASDAQ Index, SP500, Dow Jones Forecasts – NASDAQ Retreats As MongoDB Dives 25%
about 13 hours ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
REGN
profile
Regeneron Pharmaceuticals, Inc.
Follow
REGN
(
Nasdaq - US
)
N/A
980.30
+10.39 (+1.07%)
in
:
usd
•
As of: May 31, 2024 15:59
UTC -4
Open
967.00
High
980.39
Low
967.00
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
About
Regeneron Pharmaceuticals, Inc.
CEO
Leonard S. Schleifer
Headquarters
777 old saw mill river road
tarrytown, ny 10591, united states
Auditor
PricewaterhouseCoopers LLP
Employees
13,450
Share Holders
167
Website
www.regeneron.com
Industry
pharmaceuticals major
Sector
health technology
Company Overview
Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.
Regeneron Pharmaceuticals, Inc.
Statistics
Valuation Measures
Market Capitalization
2
108.02B
Enterprise Value
108.12B
Enterprise Value/EBITDA
(ttm)
25.22
Price to Earnings Ratio
(ttm)
26.04
Price to Book
(mrq)
3.95
Price to Sales
(ttm)
8.13
Price to Cash
(ytd)
22.34
Profitability
Gross Margin
(ttm)
86.34%
Operating Margin
(ttm)
32.73%
Profit Margin
(ttm)
29.34%
Return on Equity
(ttm)
16.83%
Return on Invested Capital
(ttm)
13.75%
Return on Assets
(ttm)
13.16%
Income Statement
Revenue
(ttm)
13.10B
Revenue Per Share
(ttm)
118.89
Gross Profit
(ttm)
11.31B
EBITDA
(ttm)
3
4.29B
Net Income Avi to Common
(ttm)
3.86B
Diluted EPS
(ttm)
33.85
Share Statistics
Beta (5Y Monthly)
0.17
52-Week Change
34.07%
S&P500 52-Week Change
25.03%
S&P500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding
1
110.19M
Dividend Yield
0.00%
Float
4
101.94M
%
Held by Insiders
7.48%
%
Held by Institutions
83.31%
Balance Sheet
Total Cash
(mrq)
10.52B
Total Cash Per Share
(mrq)
95.47
Total Debt
(mrq)
2.70B
Total Debt/Equity
(mrq)
10.02%
Current Ratio
(mrq)
5.27%
Quick Ratio
(mrq)
4.51%
Book Value Per Share
(mrq)
244.93
Cash Flow
Operating Cash Flow Per Share
(ytd)
13.14
Free Cash Flow
(ytd)
1.38B
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker